• Soligenix posted a net loss of $2 million, or ($0.12) per share, for the quarter ended June 30, 2026.
• Research and development expense fell 41.18% to $1 million, due to lower costs tied to the terminated Phase 3 FLASH2 trial.
• General and administrative expense was flat at $1.1 million; revenue was no revenue.
• Cash totaled about $9.8 million as of June 30, 2026, providing runway into the second quarter of 2028.
• HyBryte development was discontinued after the Phase 3 FLASH2 study; focus remains on SGX945 for Behçet's disease and ThermoVax, including CEPI funding efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608070730PR_NEWS_USPR_____PH21139) on August 07, 2026, and is solely responsible for the information contained therein.